| Phase 18 trials |
|
Phase 1
|
NCT05400122 |
Sep 2022 → Dec 2026 |
Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +5 |
David Wald |
Suspended
|
No outcome recorded
|
|
Phase 1
|
NCT05333705 |
Jul 2021 → Jul 2024 |
acute myeloid leukemia |
First Affiliated Hospital Xi'an Jiaotong University |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT04678453 |
Jan 2021 → Aug 2023 |
Alzheimer disease |
NKGen Biotech, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT04634370 |
Jan → Mar 2021 |
COVID-19 |
Hospital de Clinicas de Porto Alegre |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT03894579 |
Jul → Dec 2019 |
psoriasis |
NKGen Biotech, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03941262 |
Jul 2019 → Feb 2023 |
carcinoma, metastatic malignant neoplasm |
NKGen Biotech, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01576692 |
Apr 2012 → Oct 2014 |
neuroblastoma |
St. Jude Children's Research Hospital |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02845999 |
Nov 2009 → Jan 2013 |
digestive system cancer |
Centre Hospitalier Universitaire de Besancon |
Completed
|
No outcome recorded
|
| Phase 1/26 trials |
|
Phase 1/2
|
NCT06189963 |
Nov 2023 → Dec 2026 expected |
Alzheimer disease |
NKGen Biotech, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04211675 |
Sep 2022 → Dec 2026 expected |
neuroblastoma |
Nationwide Children's Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05099549 |
Nov 2021 → Sep 2023 |
colorectal neoplasm, head and neck squamous cell carcinoma, metastatic neoplasm, non-small cell lung carcinoma +1 |
NKGen Biotech, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT04872634 |
Jul 2021 → May 2023 |
non-small cell lung carcinoma |
NKMAX Co., Ltd. |
Unknown
|
No outcome recorded
|
|
Phase 1/2
|
NCT04464967 |
Mar 2021 → Aug 2022 |
HER2 positive breast carcinoma, cervical cancer, colorectal cancer, endometrial cancer +9 |
NKGen Biotech, Inc. |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT00303667 |
Jan 2005 → Mar 2011 |
acute myeloid leukemia |
Masonic Cancer Center, University of Minnesota |
Completed
|
No outcome recorded
|
| Phase 26 trials |
|
Phase 2
|
NCT07228078 |
Jun 2025 → Apr 2028 expected |
Alzheimer disease |
NKGen Biotech, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07202611 |
Dec 2022 → Sep 2025 overdue |
non-small cell lung carcinoma |
National Taiwan University Clinical Trial Center |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT01639456 |
Oct 2013 → Jan 2017 |
acute myeloid leukemia |
Masonic Cancer Center, University of Minnesota |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT01181258 |
Aug 2010 → Sep 2015 |
chronic lymphocytic leukemia/small lymphocytic lymphoma |
Masonic Cancer Center, University of Minnesota |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01106950 |
Jul 2010 → Oct 2011 |
acute myeloid leukemia |
Masonic Cancer Center, University of Minnesota |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT01105650 |
Jul 2010 → Apr 2014 |
breast cancer, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma |
Masonic Cancer Center, University of Minnesota |
Completed
|
No outcome recorded
|
| Comparator or background therapy3 trials |
|
Phase 1
|
NCT07443020 Background |
May 2026 → Mar 2033 expected |
malignant mesothelioma, pleural neoplasm |
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06190249 Background |
Dec 2024 → Jan 2028 |
melanoma |
James Isaacs, MD |
Withdrawn
|
No outcome recorded
Stop: Enrollment |
|
Phase 2
|
NCT00059475 Background |
Apr 2003 → May 2010 |
melanoma |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|